• - ExelonPatch 10 ExelonKapsel12 mg/d Placebo
• -ITT-LOCF Population n = 251 n = 256 n = 282
• -ADAS-Cog (n = 248) (n = 253) (n = 281)
• -Mittlere Baseline± Standardabweichung (SD) 27.0 ± 10.3 27.9 ± 9.4 28.6 ± 9.9
• -Mittlere Änderungin Woche 24 ± SD -0.6 ± 6.4 -0.6 ± 6.2 1.0 ± 6.8
• -p-Wert versus Placebo 0.005*1 0.003*1
• -ADCS-CGIC (n = 248) (n = 253) (n = 278)
• -Mittlerer Wert ± SD 3.9 ± 1.20 3.9 ± 1.25 4.2 ± 1.26
• -p-Wert versus Placebo 0.010*2 0.009*2
• -ADCS-ADL (n = 247) (n = 254) (n = 281)
• -Mittlere Baseline ± SD 50.1 ± 16.3 49.3 ± 15.8 49.2 ± 16.0
• -Mittlere Änderungin Woche 24 ± SD -0.1 ± 9.1 -0.5 ± 9.5 -2.3 ± 9.4
• -p-Wert versus Placebo 0.013*1 0.039*1
• + ExelonPatch 10 ExelonKapsel 12 mg/d Placebo
• +ITT-LOCF Population n = 251 n = 256 n = 282
• +ADAS-Cog (n = 248) (n = 253) (n = 281)
• +Mittlere Baseline ± Standardabweichung (SD) 27.0 ± 10.3 27.9 ± 9.4 28.6 ± 9.9
• +Mittlere Änderung in Woche 24 ± SD -0.6 ± 6.4 -0.6 ± 6.2 1.0 ± 6.8
• +p-Wert versus Placebo 0.005*1 0.003*1
• +ADCS-CGIC (n = 248) (n = 253) (n = 278)
• +Mittlerer Wert ± SD 3.9 ± 1.20 3.9 ± 1.25 4.2 ± 1.26
• +p-Wert versus Placebo 0.010*2 0.009*2
• +ADCS-ADL (n = 247) (n = 254) (n = 281)
• +Mittlere Baseline ± SD 50.1 ± 16.3 49.3 ± 15.8 49.2 ± 16.0
• +Mittlere Änderung in Woche 24 ± SD -0.1 ± 9.1 -0.5 ± 9.5 -2.3 ± 9.4
• +p-Wert versus Placebo 0.013*1 0.039*1
• - Exelon Patch 10 Exelon Kapsel12 mg/d Placebo
• + Exelon Patch 10 Exelon Kapsel 12 Placebo
• + mg/d
• +